10 results on '"Borrows R"'
Search Results
2. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.
- Author
-
Moore J, Middleton L, Cockwell P, Adu D, Ball S, Little MA, Ready A, Wheatley K, and Borrows R
- Subjects
- Drug Therapy, Combination, Graft Rejection epidemiology, Humans, Immunosuppressive Agents therapeutic use, Kidney Transplantation mortality, Kidney Transplantation standards, Kidney Transplantation statistics & numerical data, Mycophenolic Acid therapeutic use, Randomized Controlled Trials as Topic, Survival Analysis, Treatment Outcome, Calcineurin Inhibitors, Kidney Transplantation immunology, Mycophenolic Acid analogs & derivatives
- Abstract
Background: Limiting the exposure of kidney transplant recipients to calcineurin inhibitors (CNIs) has potential merit, but there is no clear consensus on the utility of current strategies. In an attempt to aid clarification, we conducted a systematic review and meta-analysis of randomized trials that assessed CNI sparing (minimization or elimination) with mycophenolate as sole adjunctive immunosuppression., Methods: The search strategy identified trials where CNI sparing was accompanied by the continuation of, or conversion to, mycophenolate and compared with standard or higher dose CNI therapy. Two investigators independently examined each trial for eligibility, quality, and outcome measures. Additional subgroup analyses were assessed: (1) de novo CNI sparing; (2) elective CNI sparing beyond 2 months posttransplantation; and (3) CNI sparing for transplant dysfunction., Results: Nineteen randomized controlled trials met the inclusion criteria permitting analysis of 3312 renal transplant recipients with median follow-up of 12 months. CNI sparing significantly improved glomerular filtration rate (weighted mean difference 4.4 mL/min, 95% confidence interval [CI] 2.9-5.9, P<0.001); with some evidence, albeit weak, of improved graft survival (odds ratio 0.72, 95% CI 0.52-1.01, P=0.06). Acute rejection rates were only increased after elective CNI elimination (odds ratio 2.23, 95% CI 1.57-3.17, P<0.001). There were no significant differences in mortality, malignancy or incidence of infections., Conclusions: CNI sparing strategies with adjunctive mycophenolate may play an important role in kidney transplant recipients. Improvements in short-term graft function, and possibly graft survival, are achievable. Longer term studies are needed to substantiate the short-term benefits, and refining elective CNI elimination protocols may help to reduce the risk of rejection.
- Published
- 2009
- Full Text
- View/download PDF
3. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation.
- Author
-
Borrows R, Chusney G, Loucaidou M, James A, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, and Taube D
- Subjects
- Administration, Oral, Amoxicillin administration & dosage, Amoxicillin therapeutic use, Analysis of Variance, Anti-Bacterial Agents administration & dosage, Ciprofloxacin administration & dosage, Ciprofloxacin therapeutic use, Clavulanic Acid administration & dosage, Clavulanic Acid therapeutic use, Drug Administration Schedule, Drug Therapy, Combination, Enterohepatic Circulation drug effects, Female, Humans, Immunosuppressive Agents blood, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents therapeutic use, Linear Models, Male, Mycophenolic Acid blood, Mycophenolic Acid pharmacokinetics, Mycophenolic Acid therapeutic use, Prospective Studies, Time Factors, Anti-Bacterial Agents therapeutic use, Drug Monitoring methods, Kidney Transplantation, Mycophenolic Acid analogs & derivatives
- Abstract
There is increasing evidence that monitoring predose plasma levels of mycophenolic acid (MPA) is of benefit in renal transplant recipients treated with mycophenolate mofetil (MMF). Concomitant treatment with oral antibiotics leads to a 10% to 30% reduction in MPA area under the curve (AUC)0-12, probably by reducing enterohepatic recirculation (EHR). Because of the timing of EHR (6 to 12 hours postdose), the magnitude of predose MPA level reduction may be disproportionately larger than that of AUC0-12. However, changes in predose MPA levels and the time course over which these changes occur and resolve during antibiotic treatment have not been studied. The purpose of this study was to define the extent and time course of MPA predose level reduction during antibiotic therapy. A total of 64 MMF-treated renal transplant recipients (with tacrolimus cotherapy) were prospectively studied. Clinically indicated cotherapy with either oral ciprofloxacin or amoxicillin with clavulanic acid resulted in a reduction in 12 hour predose MPA level to 46% of baseline within 3 days of antibiotic commencement. No demographic or biochemical variables were associated with the magnitude of MPA level reduction. No further fall in MPA level was seen by day 7, but MPA levels recovered spontaneously to 79% of baseline after 14 days of antibiotics. Levels normalized within 3 days of antibiotic cessation. No changes in daily MMF dose (normalized for body weight) were made during antibiotic treatment. This data should help the clinician to recognize the extent of MPA predose level reduction during antibiotic therapy, and to avoid inappropriate MMF dose escalation and potential risk of toxicity.
- Published
- 2007
- Full Text
- View/download PDF
4. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology.
- Author
-
Nankivell BJ, Wavamunno MD, Borrows RJ, Vitalone M, Fung CL, Allen RD, Chapman JR, and O'Connell PJ
- Subjects
- Adult, Cohort Studies, Cyclosporine adverse effects, Cyclosporine therapeutic use, Female, Fibrosis pathology, Graft Rejection pathology, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Kidney Glomerulus pathology, Kidney Transplantation immunology, Kidney Tubules pathology, Male, Mycophenolic Acid therapeutic use, Retrospective Studies, Time Factors, Enzyme Inhibitors therapeutic use, Graft Rejection prevention & control, Kidney Transplantation pathology, Mycophenolic Acid analogs & derivatives
- Abstract
Mycophenolate mofetil (MMF) reduces acute rejection in controlled trials of kidney transplantation and is associated with better registry graft survival. Recent experimental studies have demonstrated additional antifibrotic properties of MMF, however, human histological data are lacking. We evaluated sequential prospective protocol kidney biopsies from two historical cohorts treated with cyclosporine (CSA)-based triple therapy including prednisolone and either MMF (n = 25) or azathioprine (AZA, n = 25). Biopsies (n = 360) were taken from euglycemic kidney-pancreas transplant recipients. Histology was independently assessed by the Banff schema and electron microscopic morphometry. MMF reduced acute rejection and OKT3 use (p < 0.05) compared with AZA. MMF therapy was associated with limited chronic interstitial fibrosis, striped fibrosis and periglomerular fibrosis (p < 0.05-0.001), mesangial matrix accumulation (p < 0.01), chronic glomerulopathy scores (p < 0.05) and glomerulosclerosis (p < 0.05). MMF was associated with delayed expression of CSA nephrotoxicity, reduced arteriolar hyalinosis, striped fibrosis and tubular microcalcification (p < 0.05-0.001). The beneficial effects of MMF remained in recipients without acute rejection. Retrospective analysis shows that MMF therapy was associated with substantially reduced fibrosis in the glomerular, microvascular and interstitial compartments, and a delayed expression of CSA nephrotoxicity. These outcomes may be due to a limitation of immune-mediated injury and suggest a direct effect of reduced fibrogenesis.
- Published
- 2007
- Full Text
- View/download PDF
5. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil.
- Author
-
Borrows R, Chan K, Loucaidou M, Lawrence C, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, and Taube D
- Subjects
- Adult, Cardiovascular Diseases pathology, Creatine blood, Female, Follow-Up Studies, Graft Survival, Humans, Kidney Function Tests, Male, Mycophenolic Acid pharmacology, Risk Factors, Survival Rate, Time Factors, Immunosuppressive Agents pharmacology, Kidney Transplantation, Mycophenolic Acid analogs & derivatives, Steroids pharmacology, Tacrolimus pharmacology
- Abstract
Steroid sparing with tacrolimus and mycophenolate mofetil (MMF) is associated with good short-term renal transplant outcomes. However, late allograft dysfunction and failure remain concerns. In this study, 101 consecutive patients underwent renal transplantation with tacrolimus, MMF, and 7 days of corticosteroids only. After a median follow-up of 51 months (range 36-62), overall patient survival is 97%, and overall survival with graft function is 91%. The acute rejection rate at 12 months was 19%. Late rejection was uncommon, with only three further episodes beyond 12 months. Graft function was stable during the study, with a mean creatinine of 140 micromol/L and mean estimated creatinine clearance of 57 ml/min at the end of follow-up. Six patients developed posttransplant diabetes mellitus (three cases beyond 12 months). This steroid avoidance regimen is associated with excellent medium-term patient and graft outcomes, and a low incidence of side effects.
- Published
- 2006
- Full Text
- View/download PDF
6. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.
- Author
-
Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp JV, Owen J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, and Taube D
- Subjects
- Adult, Bacterial Infections diagnosis, Bone Marrow immunology, Diarrhea diagnosis, Dose-Response Relationship, Drug, Drug Monitoring, Female, Humans, Immunosuppression Therapy, Immunosuppressive Agents adverse effects, Leukocyte Count, Leukopenia diagnosis, Male, Middle Aged, Monitoring, Physiologic, Mycophenolic Acid adverse effects, Platelet Count, Tacrolimus blood, Thrombocytopenia diagnosis, Virus Diseases diagnosis, Graft Rejection diagnosis, Immunosuppressive Agents blood, Kidney Transplantation, Mycophenolic Acid blood
- Abstract
Studies of renal transplantation utilizing trough plasma level monitoring of mycophenolic acid (MPA) have shown inconsistent associations with toxicity and rejection. In this study, 5600 12-h trough MPA samples from 121 renal transplant recipients immunosuppressed with mycophenolate mofetil (MMF) and tacrolimus in a steroid sparing protocol (steroids for 7 days only) were sequentially analyzed. Higher MPA levels were associated with lower hemoglobin concentrations and anemia (hemoglobin <10 g/dL). Similarly, higher MPA levels were associated with lower total white cell counts and an increased incidence of leucopenia (total white cell count <4.0 x 10(9)/L). Hypoalbuminemia and renal impairment were also associated with hemotoxicity. MMF-associated diarrhea and viral infection were associated with higher MPA levels. Conversely, biopsy-proven acute rejection within the first month post-transplantation was associated with lower MPA levels. Anti-CD25 antibody induction was also associated with reduced rejection rates. No association was seen between MPA levels and platelet count, thrombocytopenia or bacterial infection. An MPA level of 1.60 mg/L early post-transplantation best discriminated patients with and without rejection, and an MPA level of 2.75 mg/L best discriminated patients with and without toxicity later post-transplantation.
- Published
- 2006
- Full Text
- View/download PDF
7. Determinants of mycophenolic acid levels after renal transplantation.
- Author
-
Borrows R, Chusney G, James A, Stichbury J, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, and Taube D
- Subjects
- Adult, Alanine Transaminase blood, Amoxicillin-Potassium Clavulanate Combination therapeutic use, Biomarkers blood, Ciprofloxacin therapeutic use, Creatinine blood, Diarrhea etiology, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection prevention & control, Graft Survival drug effects, Humans, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents therapeutic use, Male, Metronidazole therapeutic use, Middle Aged, Mycophenolic Acid pharmacokinetics, Mycophenolic Acid therapeutic use, Prodrugs pharmacokinetics, Serum Albumin metabolism, Tacrolimus blood, Tacrolimus therapeutic use, Time Factors, Treatment Outcome, Kidney Transplantation, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid blood, Prodrugs therapeutic use
- Abstract
There are data suggesting an association between mycophenolic acid (MPA) levels and acute rejection and toxicity in renal transplant recipients treated with mycophenolate mofetil (MMF), and therefore, knowledge of factors determining MPA levels may aid in accurate adjustment of MMF dosage. A total of 4970 samples taken 12 hours postdose were analyzed for MPA by immunoassay at regular intervals from the first week posttransplantation in 117 renal transplant patients immunosuppressed with MMF and tacrolimus in a steroid-sparing regimen (prednisolone for the first 7 days only). MPA levels rose in the first 3 months and stabilized thereafter; dose-normalized MPA levels rose throughout the first 12 months and subsequently stabilized. Multivariate analysis by means of a population-averaged linear regression showed positive associations between MPA level and total daily dose (P < 0.001) but not individual dose or total daily dose corrected for body weight. Positive associations were also seen with serum albumin (P = 0.01), tacrolimus trough level (P = 0.01), and female gender (P = 0.002). The association with tacrolimus levels diminished with time. Negative associations were seen between MPA level and higher estimated creatinine clearance (P < 0.001), and also with increasing alanine transaminase levels (P = 0.002), the use of oral antibiotics (P < 0.001), and infective diarrhea (P < 0.001). The latter findings may be related to changes in enterohepatic recirculation of MPA. Many clinical variables show associations with trough MPA levels. An understanding of these factors may aid therapeutic monitoring of MMF.
- Published
- 2005
- Full Text
- View/download PDF
8. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe.
- Author
-
Loucaidou M, Borrows R, Cairns T, Griffith M, Hakim N, Palmer A, Papalois V, Taube D, and McLean AG
- Subjects
- Adult, Creatinine blood, Drug Administration Schedule, Female, Follow-Up Studies, Glomerular Filtration Rate, Glucocorticoids adverse effects, Graft Rejection prevention & control, Humans, Kidney Failure, Chronic etiology, Kidney Failure, Chronic surgery, Kidney Transplantation immunology, Living Donors, Male, Middle Aged, Mycophenolic Acid therapeutic use, Safety, Time Factors, Glucocorticoids administration & dosage, Kidney Transplantation physiology, Mycophenolic Acid analogs & derivatives, Tacrolimus therapeutic use
- Abstract
Introduction: We conducted a study to assess the safety of staged, late steroid withdrawal in kidney or kidney/pancreas transplant recipients on steroids, tacrolimus, and mycophenolate mofetil (MMF)., Materials and Methods: We studied 50 patients including 33 recipients of cadaveric kidneys, eight living donor kidneys, and nine kidney-pancreas transplants. The mean time posttransplantation was 5.1 years (range 2.1 to 7.9 years). All patients were induced on prednisolone, tacrolimus, and MMF; steroids were withdrawn over 5 to 6 months. The rate of steroid reduction was altered in the face of typical steroid withdrawal symptoms (limb-girdle arthralgia/myalgia)., Results: No rejection episodes occurred during steroid withdrawal. No patient required transplant biopsy for graft dysfunction. Six patients failed steroid withdrawal: five due to arthralgia/myalgia and one due to recurrent pulmonary sarcoidosis. The unexplained rise in serum creatinine following steroid withdrawal described in several other steroid withdrawal studies was not observed in this patient cohort. The mean serum creatinine was 137 micromol/L with deltacreatinine -6.8 micromol/y per year prior to steroid cessation versus 132 micromol/L with deltacreatinine -5.9 micromol/y in the year post-steroid cessation. There were 14 patients with posttransplant diabetes mellitus in this cohort: eight on gliclazide and six on insulin. We observed a reduction in their daily insulin/gliclazide requirements from 52 units to 41 units, and 73 mg to 65 mg, respectively. Two patients became gliclazide-independent at the time of steroid cessation., Conclusions: Careful steroid withdrawal from a platform of tacrolimus and MMF is safe and not associated with a significant risk of rejection or graft dysfunction.
- Published
- 2005
- Full Text
- View/download PDF
9. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results.
- Author
-
Borrows R, Loucaidou M, Van Tromp J, Singh S, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, and Taube D
- Subjects
- Antibodies, Monoclonal therapeutic use, Creatinine blood, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection epidemiology, Graft Rejection immunology, Graft Rejection prevention & control, Graft Survival, Histocompatibility Testing, Humans, Kidney Transplantation immunology, Kidney Transplantation mortality, Mycophenolic Acid therapeutic use, Reoperation, Survival Analysis, Time Factors, Treatment Outcome, Glucocorticoids adverse effects, Kidney Transplantation physiology, Mycophenolic Acid analogs & derivatives, Tacrolimus therapeutic use
- Abstract
Although renal transplantation with a 7-day steroid-sparing regimen, tacrolimus and mycophenolate, is associated with good short-term outcomes, late allograft dysfunction and failure remain concerns. In this study 101 consecutive patients underwent renal transplantation using this immunosuppressive regimen. In addition, anti-CD25 monoclonal antibody was used in 25 high-risk patients (regrafts, two-antigen human leukocyte antigen (HLA)-DR mismatch or sensitized with anti-HLA panel reactivity >30%). After a median follow-up of 39 months (range 29 to 49), overall patient survival is 98%, with two cardiac deaths. Three other graft losses occurred, one each to early venous thrombosis, polyoma viral nephropathy, and late rejection due to noncompliance. Therefore, overall graft survival is 95%. The acute rejection rate at 6 and 12 months was 19% (no rejection occurred between months 6 and 12). Late rejection was uncommon, with only two further episodes beyond 12 months. Mean creatinine at 12 months was 144 micromol/L and mean estimated glomerular filtration rate (GFR) of 55 mL/min. Graft function was stable at 3 years with a mean creatinine of 142 micromol/L and mean estimated GFR 56 mL/min. During the study, five patients developed posttransplant diabetes mellitus (two cases beyond 12 months). Tissue-invasive cytomegalovirus disease and BK viral nephropathy each occurred in three patients, with all episodes in the first 12 months. Mean weight gain is 3.3 kg and mean blood pressure is 135/81 on an average of 1.5 antihypertensive agents. This steroid-avoidance regimen is associated with excellent medium-term patient and graft outcomes and a low incidence of side effects.
- Published
- 2005
- Full Text
- View/download PDF
10. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation.
- Author
-
Borrows R, Loucaidou M, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, and Taube D
- Subjects
- Creatinine blood, Dose-Response Relationship, Drug, Drug Administration Schedule, Ethnicity, Female, Glomerular Filtration Rate physiology, Graft Rejection epidemiology, Humans, Kidney Failure, Chronic etiology, Kidney Failure, Chronic surgery, Kidney Transplantation immunology, Male, Postoperative Complications epidemiology, Postoperative Complications immunology, Prednisolone administration & dosage, Racial Groups, Recurrence, Survival Analysis, Time Factors, Graft Survival physiology, Immunosuppressive Agents therapeutic use, Kidney Transplantation physiology, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid therapeutic use, Prednisolone therapeutic use, Tacrolimus therapeutic use
- Abstract
Evidence suggests that steroid sparing in renal transplantation is associated with good outcomes, although there are limited data regarding steroid sparing in Tacrolimus and Mycophenolate Mofetil (MMF)-based regimes. In this study we describe the use of these agents in 101 consecutive patients undergoing renal transplantation using only a 7-day course of prednisolone. Median follow-up was 33 months (range 18-44). Patient and graft survival at 1 year were 100% and 98%, respectively. The acute rejection rate at both 6 and 12 months was 19%, with two episodes beyond 12 months. Anti-CD25 monoclonal antibody (anti-CD25 mAb) was administered to 25 patients at high immunological risk: a trend toward a lower rejection rate was seen in these patients compared with those at lower risk but not receiving induction therapy (8% vs. 22%; p = 0.11). Two patients experienced recurrent rejection. Of the twenty-three rejection episodes in total, 26% showed vascular involvement. Allograft function was preserved at 12 months with a mean creatinine of 144 micromol/L and mean estimated glomerular filtration rate (GFR) of 55 mL/min. At 12 months, the incidence of post-transplant diabetes mellitus was 3.5%. This steroid-sparing regime is associated with excellent patient and graft outcomes, and a low incidence of side effects.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.